{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:04:14Z","timestamp":1786637054657,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.revmed.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:23:50Z","timestamp":1784751830000},"page":"424-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blocking interleukin-1 in pericarditis: Should we move earlier and stronger?"],"prefix":"10.1016","volume":"47","author":[{"given":"Martin","family":"Michaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Jamilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2026.04.016_bib0185","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11886-021-01549-5","article-title":"Autoimmune and autoinflammatory pericarditis: definitions and new treatments","volume":"23","author":"Bizzi","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.revmed.2026.04.016_bib0190","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2026.04.016_bib0195","first-page":"CD010652","article-title":"Colchicine for pericarditis","volume":"2014","author":"Alabed","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2026.04.016_bib0200","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.105.542738","article-title":"Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial","volume":"112","author":"Imazio","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2026.04.016_bib0205","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","article-title":"Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial","volume":"383","author":"Imazio","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2026.04.016_bib0210","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","volume":"46","author":"Schulz-Menger","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2026.04.016_bib0215","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.jacc.2025.05.023","article-title":"Concise Clinical Guidance: an ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis","volume":"86","author":"Wang","year":"2025","journal-title":"JACC"},{"key":"10.1016\/j.revmed.2026.04.016_bib0220","doi-asserted-by":"crossref","first-page":"e11776","DOI":"10.1002\/acr2.11776","article-title":"Duration of disease and long-term outcomes in patients with difficult-to-treat recurrent pericarditis: a chronic condition treated with nonsteroidal anti-inflammatory drugs, colchicine, corticosteroids, and anti-interleukin-1 agents","volume":"7","author":"Ceriani","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0225","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2026.04.016_bib0230","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/2047487319879534","article-title":"Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study","volume":"27","author":"Imazio","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.04.016_bib0240","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jacc.2023.04.046","article-title":"Treatment of idiopathic recurrent pericarditis with goflikicept: phase II\/III study results","volume":"82","author":"Myachikova","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0245","doi-asserted-by":"crossref","first-page":"1257045","DOI":"10.3389\/fmed.2023.1257045","article-title":"Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study","volume":"10","author":"Alexeeva","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.revmed.2026.04.016_bib0250","doi-asserted-by":"crossref","first-page":"vi9-vi22","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2026.04.016_bib0255","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/ard-2024-225854","article-title":"Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR\/PReS guidelines for the management of Still's disease","volume":"83","author":"Bindoli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2026.04.016_bib0260","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2026.04.016_bib0265","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11886-021-01589-x","article-title":"Interleukin-1 and the NLRP3 inflammasome in pericardial disease","volume":"23","author":"Vecchi\u00e9","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.revmed.2026.04.016_bib0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0275","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11908-011-0189-5","article-title":"Pericarditis: pathophysiology, diagnosis, and management","volume":"13","author":"Imazio","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.revmed.2026.04.016_bib0280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.tcm.2020.04.006","article-title":"The autoinflammatory side of recurrent pericarditis: enlightening the pathogenesis for a more rational treatment","volume":"31","author":"Lopalco","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.revmed.2026.04.016_bib0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.tcm.2020.04.006","article-title":"The autoinflammatory side of recurrent pericarditis: enlightening the pathogenesis for a more rational treatment","volume":"31","author":"Lopalco","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.revmed.2026.04.016_bib0290","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejim.2025.03.011","article-title":"Recurrent pericarditis with normal C-reactive protein: clinical and laboratory features, biomarkers and outcome in a non-inflammatory phenotype","volume":"135","author":"Mascolo","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2026.04.016_bib0295","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamacardio.2023.4820","article-title":"Variants at the interleukin 1 gene locus and pericarditis","volume":"9","author":"Thorolfsdottir","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0300","doi-asserted-by":"crossref","first-page":"133204","DOI":"10.1016\/j.ijcard.2025.133204","article-title":"Efficacy and safety of anakinra in idiopathic recurrent pericarditis: results from the UPACITER study","volume":"430","author":"Michaud","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12872-021-02008-3","article-title":"Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.revmed.2026.04.016_bib0310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2020.07.004","article-title":"RHAPSODY: rationale for and design of a pivotal phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1\u03b1 and interleukin-1\u03b2 trap, in patients with recurrent pericarditis","volume":"228","author":"Klein","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.revmed.2026.04.016_bib0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fmed.2020.00042","article-title":"Comparison of early vs. delayed anakinra treatment in patients with adult onset Still's disease and effect on clinical and laboratory outcomes","volume":"7","author":"Vitale","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.revmed.2026.04.016_bib0320","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/medicina60020241","article-title":"Interleukin-1 blockers in recurrent and acute pericarditis: state of the art and future directions","volume":"60","author":"Gallo","year":"2024","journal-title":"Medicina (Mex)"},{"key":"10.1016\/j.revmed.2026.04.016_bib0325","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40265-025-02169-x","article-title":"Current drug treatment for acute and recurrent pericarditis","volume":"85","author":"Bonaventura","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.revmed.2026.04.016_bib0330","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/FJC.0000000000000847","article-title":"Acute effects of interleukin-1 blockade using anakinra in patients with acute pericarditis","volume":"76","author":"Wohlford","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0335","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.anpedi.2020.08.002","article-title":"Usefulness of interleukin 1 receptor antagonist (anakinra) in refractory post-pericardiotomy syndrome","volume":"95","author":"Flores Fern\u00e1ndez","year":"2021","journal-title":"An Pediatr (Engl Ed)"},{"key":"10.1016\/j.revmed.2026.04.016_bib0340","article-title":"Rapid resolution of severe pericardial effusion using anakinra in a patient with COVID-19 vaccine-related acute pericarditis relapse: a case report","volume":"6","author":"Perna","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.revmed.2026.04.016_bib0345","first-page":"888","article-title":"Efficacy of anakinra for idiopathic and non-idiopathic pericarditis refractory or intolerant to conventional therapy","volume":"9","author":"Shaukat","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.revmed.2026.04.016_bib0350","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2665-9913(25)00023-2","article-title":"First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study","volume":"7","author":"Kernder","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0355","doi-asserted-by":"crossref","first-page":"e70106","DOI":"10.1002\/acr2.70106","article-title":"Early IL-1 inhibition in Still's disease: a window of opportunity for improving outcomes","volume":"7","author":"Bindoli","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.revmed.2026.04.016_bib0360","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:05:49Z","timestamp":1786633549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866326005448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0248866326005448"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2026.04.016","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blocking interleukin-1 in pericarditis: Should we move earlier and stronger?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}